enGene Therapeutics (ENGN) Enterprise Value (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Enterprise Value of -$258.5 million for Q2 2026, down 18.89% year-over-year from -$318.7 million in Q2 2025, and up 6.34% quarter-over-quarter from -$275.9 million in Q1 2026.
enGene Therapeutics (ENGN) Enterprise Value (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Enterprise Value for 5 consecutive years, with -$258.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Enterprise Value fell 18.89% year-over-year to -$258.5 million; the TTM figure through Apr 2026 stood at -$258.5 million (down 18.89% YoY), while the FY2025 annual figure was -$193.7 million, up 18.71% from the prior year.
- Enterprise Value grew to -$258.5 million in Q2 2026 per ENGN's latest filing, from -$275.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$20.4 million in Q4 2022 and bottomed at -$275.9 million in Q1 2026.
- Historically, Enterprise Value has averaged -$192.5 million across 5 years, with a median of -$215.6 million in 2025.
- Annual changes were most pronounced in 2023 — Enterprise Value plunged 298.95% — and 2025, when it advanced 21.64%.
- enGene Therapeutics' Enterprise Value stood at -$20.4 million in 2022, then slumped by 298.95% to -$81.5 million in 2023, then plunged by 192.35% to -$238.3 million in 2024, then grew by 18.71% to -$193.7 million in 2025, then slumped by 33.41% to -$258.5 million in 2026.
- Business Quant data shows ENGN's Enterprise Value at -$258.5 million in Q2 2026, -$275.9 million in Q1 2026, and -$193.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 2.12 Bn |
| 10 | enGene Therapeutics | 124.46 Mn | 124.46 Mn | - | -258.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -258.47 Mn |
| Jan 31, 2026 | -275.95 Mn |
| Oct 31, 2025 | -193.74 Mn |
| Jul 31, 2025 | -201.91 Mn |
| Apr 30, 2025 | -217.39 Mn |
| Jan 31, 2025 | -213.81 Mn |
| Oct 31, 2024 | -238.33 Mn |
| Jul 31, 2024 | -257.68 Mn |
| Apr 30, 2024 | -264.81 Mn |
| Jan 31, 2024 | -85.65 Mn |
| Oct 31, 2023 | -81.52 Mn |
| Oct 31, 2022 | -20.43 Mn |